Congress moves to lock in patent monopolies, raising drug and software costs
H.R. 5811 — Restoring America’s Leadership in Innovation Act of 2025 · Filed by Thomas Massie (R-KY) · 6 cosponsors · Introduced Oct 24, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill fundamentally rewrites U.S. patent law by reverting from a 'first-to-file' system (adopted in 2011) back to a 'first-to-invent' system, abolishing the Patent Trial and Appeal Board and inter partes review proceedings, broadening what can be patented (including software and genetic discoveries), and treating patents as absolute private property rights that can only be revoked by courts, not administrative agencies. The primary beneficiaries are patent holders and inventors—especially those in biotech, software, and pharmaceutical sectors—who gain stronger, longer-lasting patent protections and immunity from administrative patent challenges.
Why we flagged it
The bill's core function is to strengthen patent protections and shift enforcement power from administrative agencies to courts, benefiting patent owners at the expense of patent challengers, competitors, and consumers. It is not primarily about innovation promotion (the stated rationale) but about redistributing power and duration of patent monopolies.
What the text implies
- Reverting to first-to-invent system may create years of litigation over priority disputes, slowing innovation and increasing legal costs for inventors.
- Abolishing inter partes review removes the primary mechanism by which competitors and the public can challenge invalid patents without filing expensive federal lawsuits, effectively locking in weak patents.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies; biotechnology firms; software companies with large patent portfolios